Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Briacell Therapeutics Corp BCTXW


Primary Symbol: T.BCT Alternate Symbol(s):  BCTX

Healthcare Biotechnology
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted... see more

Recent & Breaking News (TSX:BCT)

Bondarenko Acquires 14.48% Beneficial Ownership of BriaCell Therapeutics Corp.

GlobeNewswire May 17, 2019

BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders

GlobeNewswire May 13, 2019

BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston

GlobeNewswire April 23, 2019

BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity

GlobeNewswire April 3, 2019

BriaCell Announces Clinical Trial Collaboration Agreement with Incyte

GlobeNewswire April 2, 2019

BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million

GlobeNewswire April 1, 2019

BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting

GlobeNewswire March 26, 2019

BriaCell Closes First Tranche of Previously Announced Non-Brokered Private Placement

GlobeNewswire March 25, 2019

BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering

GlobeNewswire March 20, 2019

BriaCell Welcomes BioPharma Industry Experts to its Board of Directors

GlobeNewswire March 18, 2019

BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire

GlobeNewswire March 7, 2019

BriaCell Announces C$500,000 Equity Investment by BriaCell Director

GlobeNewswire February 26, 2019

BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences

GlobeNewswire February 19, 2019

BriaCell Appoints Jamieson Bondarenko to its Board of Directors

GlobeNewswire February 12, 2019

BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference

GlobeNewswire January 2, 2019

BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference

GlobeNewswire December 6, 2018

UPDATE - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

GlobeNewswire November 20, 2018

BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

GlobeNewswire November 19, 2018

BriaCell Therapeutics Corp.’s CEO Talks Personalized Breast Cancer Treatment Technology with Uptick Newswire’s Stock Day Podcast

GlobeNewswire November 6, 2018

BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®

GlobeNewswire October 9, 2018